Aardvark Therapeutics Faces Class Action Lawsuit Over Drug Candidate Misrepresentations

LOS ANGELES, Sept. 18, 2026 /CourierPR/ -- A national shareholder rights litigation firm, Schall, Brown & Schwartz LLP (SBS), has reminded investors of a class action lawsuit against Aardvark Therapeutics, Inc. (AARD) for alleged violations of the Securities Exchange Act of 1934 and Rule 10b-5. The lawsuit centers on the company's alleged misrepresentations regarding the safety profile of its ARD-101 drug candidate and overstated clinical and commercial prospects.

According to the complaint, Aardvark Therapeutics misled investors during its February 13, 2025, initial public offering (IPO) and throughout the period from February 13, 2025, to May 14, 2026. The company is accused of making false and misleading statements to the market, which led to a significant loss for shareholders when the truth was revealed.

SBS, which has offices at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, is encouraging shareholders who purchased shares of AARD during the class period to contact the firm regarding possible lead plaintiff appointments. The deadline for those interested in participating is October 13, 2026.

Brian Schall, Andrew Brown, and David Schwartz of SBS are urging investors to contact the firm to discuss their rights free of charge. They can be reached at 310-301-3335 or through the firm's website at www.schallfirm.com.

The class has not yet been certified, and until certification occurs, investors are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

SBS, known for its expertise in securities class action lawsuits and shareholder rights litigation, is dedicated to aggressively advocating for every investor. The firm represents investors around the world and brings together the extensive experience and diverse skillsets of its founding partners.